States get cannabis control—but feds keep tax and interstate power

What it does

This bill amends the Controlled Substances Act to exempt marijuana from federal prohibition when it is manufactured, possessed, distributed, or transported in compliance with state or tribal law. It allows states and federally recognized tribes to legalize and regulate cannabis independently, removes federal criminal penalties for state-compliant marijuana activity, establishes a federal excise tax to fund marijuana regulation and enforcement, and directs the FDA to regulate marijuana products (as drugs, foods, dietary supplements, or cosmetics) without requiring premarket approval. The bill preserves federal enforcement against interstate trafficking and youth sales, and mandates a study on marijuana legalization's traffic safety effects.

Why we flagged it

The bill's core mechanism is a federalism-based exemption from the Controlled Substances Act for state-compliant marijuana activity. It is not primarily a tax bill, deregulation, or corporate carve-out, though it contains elements of all three. The dominant theme is restoring state authority over cannabis policy.

What the text implies

• Federal excise tax rate is not specified in the bill; the Attorney General and HHS Secretary have 180 days to finalize rules, creating regulatory uncertainty and potential for tax-rate capture by industry lobbying.
• Interstate transportation provision (subsection c) may create a de facto national market if states cannot block shipments from permissive jurisdictions, potentially undermining state-level price controls and tax collection.
• FDA regulation of marijuana products as foods/dietary supplements (subsection 7(c)) explicitly exempts premarket approval, creating a lighter regulatory pathway than for alcohol-containing foods, potentially enabling rapid market expansion with limited safety oversight.
• Section 418(c) exception allows distribution of medicinal marijuana to persons under 21 by those 18+, creating a legal pathway for youth access that is narrower than alcohol but broader than current law.
• Removal from CSA schedule (subsection f) is automatic upon state compliance; no affirmative DEA action is required, potentially creating conflicts with international drug treaties.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens in legalization states gain substantial legal protection, market access, and reduced criminal enforcement burden; however, the bill imposes a new federal excise tax on legal marijuana, creates FDA regulatory compliance costs that may increase consumer prices, and preserves federal prosecution of interstate trafficking and youth sales. The net effect depends on tax rate, FDA implementation, and state-level tax stacking.

Who stands to gain

• licensed marijuana businesses (removal of federal criminal liability, access to interstate commerce
• marijuana cultivators and retailers in legalization states
• Alcohol and Tobacco Tax and Trade Bureau (expanded regulatory authority and funding)
• FDA (expanded regulatory authority over marijuana products)

Named in the bill

Controlled Substances Act, Food and Drug Administration (FDA), Alcohol and Tobacco Tax and Trade Bureau (TTB), Attorney General, Secretary of Health and Human Services, Federally recognized Indian tribes, States with legalized marijuana, Comptroller General

Where it stands

8 cosponsors: 5 Republicans, 3 Democrats.

• Apr 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 17, 2025 — Referred to House Committee on Transportation and Infrastructure and House Committee on the Judiciary · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $90,000 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

David Joyce, the sponsor, reported $1,015,000 in PAC receipts in the 2026 cycle.

• Coalition for Cannabis Policy, Education and Regulation — $50,000 on 1 filing
• Students for Sensible Drug Policy — $30,000 on 2 filings
• National Cannabis Industry Association — $10,000 on 1 filing
• Americans for Nonsmokers' Rights — $0 on 2 filings

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.